Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.

The oncologist - 1 Mar 2020

Li Yong, Zhang Hai-Bo, Chen Xian, Yang Xiaobing, Ye Yongsong, Bekaii-Saab Tanios, Zheng Yaojie, Zhang Yihong

Abstract excerpt

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Growing evidence supports gene fusions as good candidates for molecularly targeted therapy in CRC. Here we describe a case of a 63-year-old man who had a radical right hemicolectomy procedure 24 months ago. Pathological diagnosis indicated colorectal adenocarcinoma with stage pT4N2bMx. During re-examination in December 2016, positron...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32162810
DOI: 10.1634/theoncologist.2019-0405
PMCID: PMC7066703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.PMID 32162810Read ↗

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma: a rare EGFR alteration reportSemantic proximity Read ↗

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsSemantic proximity Read ↗

MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.Semantic proximity Read ↗

A Rare Case of Recurrent Ovarian Cancer With NTRK1-TPM3 Gene RearrangementSemantic proximity Read ↗

[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation].Semantic proximity Read ↗

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the LiteratureSemantic proximity Read ↗

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSemantic proximity Read ↗

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Incidence and clinical significance of 491 known fusion genes in a large cohort of Japanese patients with colorectal cancer.Semantic proximity Read ↗

Gastrointestinal malignancies harbor actionable MET exon 14 deletionsSemantic proximity Read ↗

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerSemantic proximity Read ↗

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.